Can American drug pricing practices continue?
The United States Government is the largest biopharmaceuticals customer in the world. Medicare alone pays for more prescription drugs than Japan, Germany and the UK combined. However, unlike most other nations, the U.S. has no formal Health-technology-Assessment (HTA) body. The American system enables quicker access to new therapeutics and leaves questions about value to the market.
This latest brief via EY-Parthenon examines the continued feasibility of the current U.S. approach.